Abstract 1353P
Background
TP53 variants are common in NSCLC and have been reported as predictive of response and prognostic of poor outcome in EGFR-mutant NSCLC. The impact of TP53 co-mutation in NSCLCs carrying rarer driver mutations with approved targeted treatments is unclear.
Methods
Records of 236 patients with rare driver mutation positive NSCLC at Princess Margaret Cancer Centre were reviewed. Associations between TP53 status, baseline demographics and outcomes (response [ORR], survival [OS], progression-free survival [PFS]), were investigated. ORR (to first-line targeted therapy only) was compared via Fisher’s exact test. OS and PFS were compared by Kaplan-Meier estimates, and Cox regression adjusted for stage at diagnosis with wildtype (WT) as reference.
Results
TP53 variants were found in 88/236 (37%; table) with two+ driver mutations in 22 (9%). There were no significant demographic differences between TP53-mutated (MUT) and WT except for smoking status (never smokers 58% TP53-MUT v 70% TP53-WT, p=0.002). ORR to first-line targeted treatment was 54% vs 71% in the TP53-MUT and WT cohorts, respectively (p=0.09). More patients with TP53-MUT cancer had progressive disease (PD) as best response (27% v 8%, p=0.005). Median PFS was 19.6 mos for TP53-MUT (95% CI 14.4-24.3) v 42.7 mos for WT (CI 31-72.9) (stage-adjusted hazard ratio (aHR) 2.35, CI 1.62-3.39; p<0.001). Median OS was significantly shorter in the TP53-MUT cohort at 20.9 mos (CI 17.3-30.7) compared to 66.4 mos (CI 54.8-not reached) (aHR 3.30, CI 2.20-4.95; p<0.001). In a subset with fusion mutations (ALK, ROS1, RET, NRG1), we saw similar trends in ORR (67% TP53-MUT v 88% WT, p=0.11), PFS (aHR 2.83, CI 1.52-5.27; p=0.001), and OS (aHR 5.00, CI 2.42-10.33; p<0.001). Table: 1353P
TP53 wildtype (n=148) N (%) | TP53 mutated (n=88) N (%) | p value | |
Median age (range) | 62.1 (31.8, 91.0) | 64.8 (22.0, 90.0) | 0.40 |
Female sex | 91 (61%) | 49 (56%) | 0.46 |
Never smoker | 99 (70%) | 49 (58%) | 0.06 |
Adenocarcinoma | 141 (95%) | 83 (94%) | 0.99 |
Stage at diagnosis I/II III IV | 32 (22%) 31 (21%) 85 (57%) | 16 (18%) 15 (17%) 57 (65%) | 0.54 |
Brain metastases at any time | 49 (36%) | 31 (37%) | 0.90 |
Driver mutations ALK BRAF V600E EGFR exon 20 ins Uncommon EGFR HER2 exon 20 ins HER2 oncogenic SNV KIT MET exon 14 skip NRG1 RET ROS1 Multiple | 44 6 3 3 27 4 0 18 2 10 15 16 | 9 1 5 3 21 6 1 17 0 6 8 11 | |
Response to first line targeted treatment CR PR SD PD Non-evaluable | n=100 1 (1%) 64 (65%) 19 (19%) 8 (8%) 8 (7%) | n=49 0 22 (45%) 6 (12%) 13 (27%) 8 (14%) | 0.005 |
Conclusions
TP53 co-mutation with multiple rare driver mutations is predictive of poor response to targeted treatments and prognostic of shorter OS and PFS in NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Feng: Financial Interests, Personal, Invited Speaker: AstraZeneca. N. Leighl: Financial Interests, Personal, Other, CME/independent lectures: MSD, BMS, Hoffmann LaRoche, EMD Serono; Financial Interests, Personal, Invited Speaker, independent lectures: Novartis, Takeda; Financial Interests, Personal, Advisory Board: Puma Biotechnology; Financial Interests, Institutional, Research Grant: Amgen, AstraZeneca, Array, Bayer, EMD Serono, Guardant Health, Lilly, MSD, Pfizer, Roche, Takeda, Janssen. G. Liu: Financial Interests, Personal, Advisory Board: Takeda, AstraZeneca, Pfizer, Lilly, Merck, Novartis, Jazz, Bristol Myers Squibb, EMD Serono; Financial Interests, Institutional, Research Grant: Boehringer Ingelheim, Takeda, AstraZeneca, EMD Serono. P. Bradbury: Financial Interests, Personal, Advisory Role: Merck, AbbVie, Eli Lilly, Pfizer, Boehringer Ingelheim; Non-Financial Interests, Personal, Advisory Board: Mirati, AstraZeneca. A. Sacher: Financial Interests, Institutional, Coordinating PI: Genentech-Roche, BMS, AstraZeneca; Financial Interests, Institutional, Local PI: Amgen, Iovance, CRISPR Therapeutics, Merck, Pfizer, GSK, Spectrum, Lilly. F.A. Shepherd: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Institutional, Local PI: AstraZeneca, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
1027P - An open-label, multicenter, phase I/II study of GI-101, CD80-IgG4 Fc-IL2v, in advanced solid tumors (Part A of GII-101-P101; KEYNOTE-B59)
Presenter: Byoung Chul Cho
Session: Poster session 19
1028P - Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors
Presenter: Daphne Day
Session: Poster session 19
1029P - Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)
Presenter: Anthony Olszanski
Session: Poster session 19
1030P - Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors
Presenter: Emiliano Calvo
Session: Poster session 19
1031P - ANV419, a selective IL-2Rβ/γ agonist in patients with relapsed/refractory advanced solid tumors
Presenter: Emiliano Calvo
Session: Poster session 19
1032P - A phase II study of sintilimab plus IBI310 for Epstein-Barr virus (EBV)-associated gastric cancer
Presenter: Zhi Peng
Session: Poster session 19
1033P - First-in-human study of MALT1 inhibitor MPT-0118: Results from monotherapy dose escalation in advanced or metastatic refractory solid tumors
Presenter: Aung Naing
Session: Poster session 19
1034P - Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy
Presenter: Alexander Starodub
Session: Poster session 19
1035P - Phase I dose escalation study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors
Presenter: Ho Yeong Lim
Session: Poster session 19
1036P - A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors
Presenter: Junli Xue
Session: Poster session 19